Christopher Rovaldi

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Keith Regnante, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Rovaldi:

Form 4 holding Chief Operating Officer

Keros Therapeutics, Inc.

Security class
Common Stock
Shares / value
60,000
Estimated value
$2,640,600
Report date
18 Feb 2025
Price
$44.01
Ownership
Direct

Insider Reports Filed by Christopher Rovaldi

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .